Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 11OTHER_GOV 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Head & Neck 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Colorectal Neoplasms 115Rectal Neoplasms 77Colonic Neoplasms 71Pancreatic Neoplasms 38Stomach Neoplasms 34Esophageal Neoplasms 29Anus Neoplasms 18Adenocarcinoma Of Esophagus 17Carcinoma, Non-Small-Cell Lung 14Carcinoma, Hepatocellular 14Breast Neoplasms 14Biliary Tract Neoplasms 14Neoplasm Metastasis 11Liver Neoplasms 11Lung Neoplasms 10Sarcoma 9Hepatoblastoma 9Gastrointestinal Stromal Tumors 9Ovarian Neoplasms 8Neoplasms 8HIV Infections 8Prostatic Neoplasms 7Gallbladder Neoplasms 7Esophageal Squamous Cell Carcinoma 7Anal Canal Carcinoma 7Small Cell Lung Carcinoma 6Precancerous Conditions 6Neuroblastoma 6Uterine Cervical Neoplasms 5Osteosarcoma 5

Interventions

Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Drug-Related Side Effects and Adverse Reactions × Gastrointestinal × Clear all
NCT00075868 2015-11-17

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Radiation Therapy Oncology Group

Phase 3 Completed
233 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡